Best for
Melasma & stubborn hyperpigmentation
Studied concentration
0.1–0.3% in clinical trials
Time to results
4–8 weeks in trials
4-Butylresorcinol (sometimes labelled 4-n-butylresorcinol, or sold under trade names like Sepiwhite or Rucinol) is a resorcinol-derived brightening active that’s less of a household name than hydroquinone or niacinamide, but has real laboratory and clinical trial data behind it — including a multicentric study run specifically on Indian skin.
What 4-butylresorcinol does for skin
- Blocks melanin production at two points, not one — it inhibits both tyrosinase and tyrosinase-related protein-1 (TRP-1), the enzymes most responsible for melanin synthesis, giving it a broader mechanism than single-target actives like kojic acid
- Tests as one of the more potent tyrosinase inhibitors in lab studies — in vitro research has measured its enzyme-inhibiting concentration at roughly 20 times lower (i.e. stronger) than kojic acid, and considerably lower than hydroquinone or arbutin, which need much higher concentrations to achieve comparable inhibition in a test tube
- Has clinical trial data collected specifically on Indian skin — a multicentric study across two Indian medical colleges recorded roughly a 56% drop in melasma severity scores (MASI) over 8 weeks using a 0.3% cream, with no adverse reactions reported among the 52 participants
Worth being clear-eyed about: lab potency against an isolated enzyme doesn’t automatically translate into proportionally faster real-world fading. The clinical trials below still ran over the same 8-week window typically used to test other brightening actives — the results were genuinely positive within that timeframe, just not instantaneous.
What percentage of 4-butylresorcinol should you use
Published clinical research has concentrated on two concentrations, and both showed measurable improvement within 8 weeks without significant reported adverse effects — a notably clean safety record compared to some higher-strength brightening actives.
| Concentration | What the evidence shows |
|---|---|
| 0.1% | Tested in a randomized, double-blind, vehicle-controlled split-face trial (20 women with melasma) — melanin index dropped meaningfully by week 8; mild, transient erythema or itching appeared in about 10% of participants early on and resolved by week 8 |
| 0.3% | Tested in a multicentric Indian study (52 participants, Fitzpatrick III–V, epidermal-type melasma) — roughly a 56% reduction in MASI severity score over 8 weeks, with no adverse reactions reported |
| Above 0.3% | Not meaningfully represented in published clinical trials — most formulations stay within the studied range rather than pushing higher |
An honest note on the evidence
4-Butylresorcinol’s lab potency against tyrosinase is well documented, and the two human trials available are encouraging. But the total published clinical research is still much smaller than what exists for hydroquinone, niacinamide, or vitamin C — fewer participants, shorter follow-up windows, and far less long-term, real-world use data across diverse populations. Some ingredient marketing describes it as unconditionally safe in pregnancy; that specific claim isn’t backed by dedicated pregnancy safety studies we could find, so it’s worth treating the same as most active ingredients in pregnancy — a conversation with your doctor rather than an assumption either way.
Who should use 4-butylresorcinol
Worth considering for those dealing with melasma or stubborn hyperpigmentation, particularly on Indian and other darker skin tones (Fitzpatrick III–V), where much of the ingredient’s clinical data was actually collected. It may also suit people who’ve tried gentler actives like niacinamide or alpha arbutin without enough improvement and want a more potent option that, unlike hydroquinone in India, isn’t prescription-only.
What to pair 4-butylresorcinol with
As with most potent actives, patch test first and add it to your routine on its own before layering in other new products, so you can actually tell what your skin is responding to.
Frequently asked questions
Is 4-butylresorcinol the same as arbutin?
No — despite the similar-sounding territory, they’re structurally different. 4-Butylresorcinol is a resorcinol derivative that inhibits tyrosinase directly, while alpha arbutin works partly through a slow, controlled hydroquinone-release mechanism. Because they act through different routes, they can generally be used together.
Is it well studied on Indian skin tones specifically?
The largest published clinical trial was conducted on Indian participants with Fitzpatrick III–V skin and reported no adverse reactions over 8 weeks at 0.3% — genuinely useful for melanin-rich skin specifically, though a 52-person study is still a modest sample size.
Can I use it with tranexamic acid or hydroquinone?
There’s no known interaction that makes combining them unsafe, and pairing actives that target pigmentation through different mechanisms is common practice. Introduce one at a time and watch for irritation, especially if you’re already using a prescription-strength active like hydroquinone.
How does it compare to hydroquinone?
In laboratory enzyme-inhibition testing, 4-butylresorcinol has shown stronger tyrosinase-blocking potency than hydroquinone at equivalent concentrations. But direct head-to-head clinical trials comparing the two on the same patients are limited, so it’s more accurate to call it a promising, well-tolerated alternative than a proven replacement.